Trial Profile

A Phase 1/1b Study of Single and Multiple Ascending Doses of TLC 6740 in Healthy Subjects, Including Evaluation of Food Effect and Potential Drug-Drug Interactions, and Preliminary Safety and Efficacy in Subjects With Obesity, With or Without Diabetes

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirzepatide (Primary) ; TLC 6740 (Primary) ; TLC 6740 (Primary) ; Itraconazole; Omeprazole; Voriconazole
Indications Diabetes mellitus; Lipodystrophy; Metabolic disorders; Non-alcoholic steatohepatitis; Obesity
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors OrsoBio

04 Nov 2025 According to an OrsoBio media release, the data from the trial will be presented at the ObesityWeek 2025.
04 Nov 2025 Results published in the Media Release
14 Aug 2025 Planned number of patients changed from 514 to 564.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com